Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
DORTMUND, Germany, Dec. 13, 2016 -- PROTAGEN AG, a leading provider of pharma development services, companion diagnostics and novel diagnostic tests in the fields of immuno-oncology and autoimmune disease, today announced the launch of NavigAID SSc, a disease stratification assay designed to support pharmaceutical and biotechnology companies with their Systemic Sclerosis (SSc) drug development efforts.
SSc is a severe autoimmune disease of the connective tissue with extreme heterogeneity in clinical presentation and unpredictable clinical course. It is characterized by tissue fibrosis and vascular injury in the skin and internal organs.
NavigAID SSc is the latest addition to the Protagen NavigAID product line. Building on the successful launch of NavigAID SLE in April 2015, NavigAID SSc is a novel stratification assay that enables the distinct segregation of patient subgroups via the measurement of serum biomarkers, thereby increasing the probability of success in both SSc treatment and clinical drug development.
“The World Scleroderma Foundation reports that approximately 2.5 million individuals worldwide suffer from SSc, which in its more aggressive form is the most fatal of all rheumatologic disorders. Unfortunately, the extreme clinical diversity of the disease means that no two patients are truly alike, a fact that has hindered much-needed medical progress,” said Bernd Kirschbaum, former Merck Pharma Executive and Chairman of the Protagen Board of Directors. “Addressing the SSc heterogeneity challenge is crucial for the clinical development of effective and curative therapies. The new NavigAID SSc does exactly this.”
Protagen NavigAID SSc has been specifically developed to tackle the heterogeneity challenge associated with SSc and it facilitates the development of new therapies by employing existing and new proprietary serum biomarkers. Taking a unique disease stratification approach, NavigAID SSc enables differential diagnosis, risk stratification and prediction of organ involvement. Additionally, NavigAID SSc has the potential to provide the basis for treatment-specific companion diagnostics (CDx).
“Our innovative NavigAID concept has been specifically designed to address the growing unmet need for novel diagnostic biomarkers and assays for precise disease characterization, patient stratification and therapy response prediction. As such, it is set to benefit any new SSc clinical development program,” added Georg Lautscham, Chief Business Officer at Protagen. “Continuing on this path, we are currently working on additional NavigAID product line extensions across other therapies and indications, such as checkpoint inhibitor therapies in immuno-oncology, cancer vaccines, rheumatoid arthritis and Sjögren’s Syndrome.”
About Systemic Sclerosis
SSc is a rare, complex autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. Despite numerous efforts in recent years, no drug has been approved to date for the treatment of SSc, with the disease’s remarkably heterogeneous nature being the main hurdle for successful SSc drug development. Autoantibodies, which have been found to be stable and consistent within SSc patients over time, have been strongly associated with patterns of organ involvement and disease outcomes. As such, understanding their mechanisms of action is essential to the clinical management of SSc.
About Protagen – Diagnostics Differentiated
Headquartered in Dortmund Germany, Protagen specializes in Pharma development services, companion diagnostics and novel diagnostics, in the field of immuno-oncology and autoimmune disease. Protagen uses its proprietary SeroTag biomarker discovery platform to identify valuable biomarkers that support Pharma development and its NavigAID products to personalize treatment with targeted therapies. With state-of-the-art bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies for cancer and autoimmune disease patients.
For more information, please visit www.protagen.com
Company Contact: Dr. Georg Lautscham Chief Business Officer Protagen AG Otto-Hahn-Str. 15 44227 Dortmund T +49 231 9742 6300 [email protected] Media Inquiries: Matt Clawson SVP, Managing Director Pure Communications San Clemente, CA USA T +1 (949) 370-8500 [email protected]
